COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTICORPS SE LIANT DE MANIÈRE SPÉCIFIQUE À L'EXTRÉMITÉ N-TERMINALE DE LA LYSYL-ARNT SYNTHÉTASE EN TANT QUE PRINCIPE ACTIF POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE LIÉE À LA MIGRATION DES CELLULES IMMUNITAIRES
The present invention relates to a novel use of an antibody biding specifically to the N-terminus of lysyl-tRNA synthase and, more particularly, to a pharmaceutical composition comprising an antibody biding specifically to an epitope including the sequence of SEQ ID NO: 117 in the N-terminal domain of lysyl-tRNA synthase (KRS) or a functional fragment thereof as an effective ingredient for preventing and treating an immune cell migration-related disease. A KRS N-terminus-specific antibody provided by the present invention can regulate the migration of immune cells, thereby exhibiting very remarkable effects in the prevention, alleviation, and treatment of immune cell migration-related diseases.
